Summary
Global Markets Direct’s, ‘Diabetic Nephropathy - Pipeline Review, H2 2016’, provides an overview of the Diabetic Nephropathy pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Diabetic Nephropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy
- The report reviews pipeline therapeutics for Diabetic Nephropathy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Diabetic Nephropathy therapeutics and enlists all their major and minor projects
- The report assesses Diabetic Nephropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Diabetic Nephropathy
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Diabetic Nephropathy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Diabetic Nephropathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AbbVie Inc
Ampio Pharmaceuticals, Inc.
Antisense Therapeutics Limited
Araim Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc.
Astellas Pharma Inc.
AstraZeneca Plc
Bayer AG
BiOrion Technologies B.V.
Boehringer Ingelheim GmbH
Cellmid Limited
ChemoCentryx, Inc.
CSL Limited
Daiichi Sankyo Company, Limited
Dimerix Bioscience Pty Ltd
Dong Wha Pharma Co., Ltd.
Dynamis Therapeutics, Inc.
Eli Lilly and Company
Galectin Therapeutics, Inc.
GenKyoTex S.A.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Glucox Biotech AB
GNI Group Ltd.
Islet Sciences, Inc.
Jenrin Discovery, Inc.
Johnson & Johnson
Mallinckrodt Plc
Mesoblast Limited
Mitsubishi Tanabe Pharma Corporation
MorphoSys AG
Noxxon Pharma AG
Omeros Corporation
Otsuka Holdings Co., Ltd.
PhytoHealth Corporation
ProMetic Life Sciences Inc.
Serodus ASA
Takeda Pharmaceutical Company Limited
Theravance Biopharma, Inc.
Tobira Therapeutics, Inc.
Vascular Pharmaceuticals, Inc.
Vicore Pharma AB
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Diabetic Nephropathy Overview 9
Therapeutics Development 10
Pipeline Products for Diabetic Nephropathy - Overview 10
Pipeline Products for Diabetic Nephropathy - Comparative Analysis 11
Diabetic Nephropathy - Therapeutics under Development by Companies 12
Diabetic Nephropathy - Therapeutics under Investigation by Universities/Institutes 15
Diabetic Nephropathy - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Diabetic Nephropathy - Products under Development by Companies 20
Diabetic Nephropathy - Products under Investigation by Universities/Institutes 23
Diabetic Nephropathy - Companies Involved in Therapeutics Development 24
AbbVie Inc 24
Ampio Pharmaceuticals, Inc. 25
Antisense Therapeutics Limited 26
Araim Pharmaceuticals, Inc. 27
Arena Pharmaceuticals, Inc. 28
Astellas Pharma Inc. 29
AstraZeneca Plc 30
Bayer AG 31
BiOrion Technologies B.V. 32
Boehringer Ingelheim GmbH 33
Cellmid Limited 34
ChemoCentryx, Inc. 35
CSL Limited 36
Daiichi Sankyo Company, Limited 37
Dimerix Bioscience Pty Ltd 38
Dong Wha Pharma Co., Ltd. 39
Dynamis Therapeutics, Inc. 40
Eli Lilly and Company 41
Galectin Therapeutics, Inc. 42
GenKyoTex S.A. 43
Gilead Sciences, Inc. 44
GlaxoSmithKline Plc 45
Glucox Biotech AB 46
GNI Group Ltd. 47
Islet Sciences, Inc. 48
Jenrin Discovery, Inc. 49
Johnson & Johnson 50
Mallinckrodt Plc 51
Mesoblast Limited 52
Mitsubishi Tanabe Pharma Corporation 53
MorphoSys AG 54
Noxxon Pharma AG 55
Omeros Corporation 56
Otsuka Holdings Co., Ltd. 57
PhytoHealth Corporation 58
ProMetic Life Sciences Inc. 59
Serodus ASA 60
Takeda Pharmaceutical Company Limited 61
Theravance Biopharma, Inc. 62
Tobira Therapeutics, Inc. 63
Vascular Pharmaceuticals, Inc. 64
Vicore Pharma AB 65
Diabetic Nephropathy - Therapeutics Assessment 66
Assessment by Monotherapy Products 66
Assessment by Target 67
Assessment by Mechanism of Action 70
Assessment by Route of Administration 74
Assessment by Molecule Type 76
Drug Profiles 78
11-RVIVIT - Drug Profile 78
A-717 - Drug Profile 79
Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug Profile 80
APD-371 - Drug Profile 81
APX-115 - Drug Profile 82
ASP-8232 - Drug Profile 83
ATL-1103 - Drug Profile 84
atrasentan hydrochloride - Drug Profile 91
baricitinib - Drug Profile 93
BI-703704 - Drug Profile 100
BOT-191 - Drug Profile 101
C-21 - Drug Profile 102
canagliflozin - Drug Profile 104
CCX-140 - Drug Profile 111
cenicriviroc mesylate - Drug Profile 115
cibinetide - Drug Profile 122
corticotropin - Drug Profile 125
CS-3150 - Drug Profile 127
CSL-346 - Drug Profile 129
Cyndacel-M - Drug Profile 130
danazol - Drug Profile 131
DMX-250 - Drug Profile 135
DT-23552 - Drug Profile 136
DW-1029M - Drug Profile 137
DYN-12 - Drug Profile 138
emapticap pegol - Drug Profile 140
finerenone - Drug Profile 142
GKT-136901 - Drug Profile 144
GKT-831 - Drug Profile 145
GRMD-02 - Drug Profile 148
GW-610742 - Drug Profile 158
IP-9 - Drug Profile 159
JD-5037 - Drug Profile 160
JNJ-39933673 - Drug Profile 161
MG-132 - Drug Profile 162
Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications - Drug Profile 163
MOR-107 - Drug Profile 165
MPC-300IV - Drug Profile 166
MT-3995 - Drug Profile 170
Nephrilin - Drug Profile 171
Orbcel-M - Drug Profile 172
oxypurinol - Drug Profile 173
PBI-4050 - Drug Profile 174
PBI-4547 - Drug Profile 179
PHN-033 - Drug Profile 180
pirfenidone - Drug Profile 181
probucol - Drug Profile 182
selonsertib - Drug Profile 183
SER-150 - Drug Profile 184
Small Molecule to Inhibit NOX-4 for Diabetic Nephropathy - Drug Profile 187
Small Molecules for Diabetic Nephropathy - Drug Profile 188
Small Molecules to Inhibit Heparanase for Metastatic Cancer and Diabetic Nephropathy - Drug Profile 189
Small Molecules to Target O2 Radical and HMGCR for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders - Drug Profile 190
SP-20202 - Drug Profile 192
TAK-272 - Drug Profile 193
TBE-31 - Drug Profile 194
TD-0714 - Drug Profile 195
VPI-2690B - Drug Profile 197
VS-105 - Drug Profile 198
XRX-108 - Drug Profile 199
XRX-221 - Drug Profile 200
Diabetic Nephropathy - Dormant Projects 201
Diabetic Nephropathy - Discontinued Products 204
Diabetic Nephropathy - Product Development Milestones 205
Featured News & Press Releases 205
Appendix 215
Methodology 215
Coverage 215
Secondary Research 215
Primary Research 215
Expert Panel Validation 215
Contact Us 215
Disclaimer 216
List of Tables
Number of Products under Development for Diabetic Nephropathy, H2 2016 14
Number of Products under Development for Diabetic Nephropathy - Comparative Analysis, H2 2016 15
Number of Products under Development by Companies, H2 2016 16
Number of Products under Development by Companies, H2 2016 (Contd..1) 17
Number of Products under Development by Companies, H2 2016 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H2 2016 19
Comparative Analysis by Late Stage Development, H2 2016 20
Comparative Analysis by Clinical Stage Development, H2 2016 21
Comparative Analysis by Early Stage Development, H2 2016 22
Comparative Analysis by Unknown Stage Development, H2 2016 23
Products under Development by Companies, H2 2016 24
Products under Development by Companies, H2 2016 (Contd..1) 25
Products under Development by Companies, H2 2016 (Contd..2) 26
Products under Investigation by Universities/Institutes, H2 2016 27
Diabetic Nephropathy - Pipeline by AbbVie Inc, H2 2016 28
Diabetic Nephropathy - Pipeline by Ampio Pharmaceuticals, Inc., H2 2016 29
Diabetic Nephropathy - Pipeline by Antisense Therapeutics Limited, H2 2016 30
Diabetic Nephropathy - Pipeline by Araim Pharmaceuticals, Inc., H2 2016 31
Diabetic Nephropathy - Pipeline by Arena Pharmaceuticals, Inc., H2 2016 32
Diabetic Nephropathy - Pipeline by Astellas Pharma Inc., H2 2016 33
Diabetic Nephropathy - Pipeline by AstraZeneca Plc, H2 2016 34
Diabetic Nephropathy - Pipeline by Bayer AG, H2 2016 35
Diabetic Nephropathy - Pipeline by BiOrion Technologies B.V., H2 2016 36
Diabetic Nephropathy - Pipeline by Boehringer Ingelheim GmbH, H2 2016 37
Diabetic Nephropathy - Pipeline by Cellmid Limited, H2 2016 38
Diabetic Nephropathy - Pipeline by ChemoCentryx, Inc., H2 2016 39
Diabetic Nephropathy - Pipeline by CSL Limited, H2 2016 40
Diabetic Nephropathy - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 41
Diabetic Nephropathy - Pipeline by Dimerix Bioscience Pty Ltd, H2 2016 42
Diabetic Nephropathy - Pipeline by Dong Wha Pharma Co., Ltd., H2 2016 43
Diabetic Nephropathy - Pipeline by Dynamis Therapeutics, Inc., H2 2016 44
Diabetic Nephropathy - Pipeline by Eli Lilly and Company, H2 2016 45
Diabetic Nephropathy - Pipeline by Galectin Therapeutics, Inc., H2 2016 46
Diabetic Nephropathy - Pipeline by GenKyoTex S.A., H2 2016 47
Diabetic Nephropathy - Pipeline by Gilead Sciences, Inc., H2 2016 48
Diabetic Nephropathy - Pipeline by GlaxoSmithKline Plc, H2 2016 49
Diabetic Nephropathy - Pipeline by Glucox Biotech AB, H2 2016 50
Diabetic Nephropathy - Pipeline by GNI Group Ltd., H2 2016 51
Diabetic Nephropathy - Pipeline by Islet Sciences, Inc., H2 2016 52
Diabetic Nephropathy - Pipeline by Jenrin Discovery, Inc., H2 2016 53
Diabetic Nephropathy - Pipeline by Johnson & Johnson, H2 2016 54
Diabetic Nephropathy - Pipeline by Mallinckrodt Plc, H2 2016 55
Diabetic Nephropathy - Pipeline by Mesoblast Limited, H2 2016 56
Diabetic Nephropathy - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 57
Diabetic Nephropathy - Pipeline by MorphoSys AG, H2 2016 58
Diabetic Nephropathy - Pipeline by Noxxon Pharma AG, H2 2016 59
Diabetic Nephropathy - Pipeline by Omeros Corporation, H2 2016 60
Diabetic Nephropathy - Pipeline by Otsuka Holdings Co., Ltd., H2 2016 61
Diabetic Nephropathy - Pipeline by PhytoHealth Corporation, H2 2016 62
Diabetic Nephropathy - Pipeline by ProMetic Life Sciences Inc., H2 2016 63
Diabetic Nephropathy - Pipeline by Serodus ASA, H2 2016 64
Diabetic Nephropathy - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 65
Diabetic Nephropathy - Pipeline by Theravance Biopharma, Inc., H2 2016 66
Diabetic Nephropathy - Pipeline by Tobira Therapeutics, Inc., H2 2016 67
Diabetic Nephropathy - Pipeline by Vascular Pharmaceuticals, Inc., H2 2016 68
Diabetic Nephropathy - Pipeline by Vicore Pharma AB, H2 2016 69
Assessment by Monotherapy Products, H2 2016 70
Number of Products by Stage and Target, H2 2016 72
Number of Products by Stage and Mechanism of Action, H2 2016 75
Number of Products by Stage and Route of Administration, H2 2016 79
Number of Products by Stage and Molecule Type, H2 2016 81
Diabetic Nephropathy - Dormant Projects, H2 2016 205
Diabetic Nephropathy - Dormant Projects (Contd..1), H2 2016 206
Diabetic Nephropathy - Dormant Projects (Contd..2), H2 2016 207
Diabetic Nephropathy - Discontinued Products, H2 2016 208
List of Figures
Number of Products under Development for Diabetic Nephropathy, H2 2016 14
Number of Products under Development for Diabetic Nephropathy - Comparative Analysis, H2 2016 15
Number of Products under Development by Companies, H2 2016 16
Number of Products under Investigation by Universities/Institutes, H2 2016 19
Comparative Analysis by Clinical Stage Development, H2 2016 21
Comparative Analysis by Early Stage Products, H2 2016 22
Assessment by Monotherapy Products, H2 2016 70
Number of Products by Top 10 Targets, H2 2016 71
Number of Products by Stage and Top 10 Targets, H2 2016 71
Number of Products by Top 10 Mechanism of Actions, H2 2016 74
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 74
Number of Products by Routes of Administration, H2 2016 78
Number of Products by Stage and Routes of Administration, H2 2016 78
Number of Products by Top 10 Molecule Types, H2 2016 80
Number of Products by Stage and Top 10 Molecule Types, H2 2016 80
